Larry G. Edwards
Chief Executive Officer chez Aicuris Anti-Infective Cures AG
Profil
Larry G.
Edwards is currently the Chief Executive Officer at Aicuris Anti-Infective Cures AG, Director at La Jolla Pharmaceutical II BV, Director at UTILITY therapeutics Ltd., and Director at Clarametyx Biosciences, Inc. Previously, he served as the President & Chief Executive Officer at La Jolla Pharmaceutical Co. from 2022 to 2023, President, Chief Executive Officer & Director at Tetraphase Pharmaceuticals, Inc. from 2019 to 2020, President & Chief Executive Officer at La Jolla Pharma LLC, President & Chief Executive Officer at Tetraphase Pharmaceuticals Ireland Ltd., Director-Global Marketing at Merck & Co., Inc. from 2010 to 2014, and Senior Director-Marketing at Cubist Pharmaceuticals LLC from 2014 to 2015.
Mr. Edwards holds an MBA from Boston University and an undergraduate degree from The Ohio University.
Postes actifs de Larry G. Edwards
| Sociétés | Poste | Début |
|---|---|---|
Clarametyx Biosciences, Inc.
 Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | Director/Board Member | - |
UTILITY therapeutics Ltd.
 UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Director/Board Member | 01/03/2021 |
La Jolla Pharmaceutical II BV
 La Jolla Pharmaceutical II BV Medical/Nursing ServicesHealth Services Part of Innoviva, Inc., La Jolla Pharmaceutical II BV provides healthcare services. The private company is based in Amsterdam, Netherlands. | Director/Board Member | - |
Aicuris Anti-Infective Cures AG
 Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Chief Executive Officer | 01/04/2023 |
Anciens postes connus de Larry G. Edwards
| Sociétés | Poste | Fin |
|---|---|---|
| LA JOLLA PHARMACEUTICAL COMPANY | Chief Executive Officer | 01/04/2023 |
La Jolla Pharma LLC
 La Jolla Pharma LLC Pharmaceuticals: MajorHealth Technology Part of Innoviva, Inc., La Jolla Pharma LLC is a pharmaceutical company that manufactures pharmaceutical products. The private company is based in Dover, DE. | Chief Executive Officer | 01/04/2023 |
| TETRAPHASE PHARMACEUTICALS, INC. | Chief Executive Officer | 28/07/2020 |
| CUBIST PHARMACEUTICALS INC | Sales & Marketing | 01/07/2015 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2010 |
Formation de Larry G. Edwards
| Boston University | Masters Business Admin |
| The Ohio University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
La Jolla Pharmaceutical II BV
La Jolla Pharmaceutical II BV Medical/Nursing ServicesHealth Services Part of Innoviva, Inc., La Jolla Pharmaceutical II BV provides healthcare services. The private company is based in Amsterdam, Netherlands. | Health Services |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Health Technology |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Commercial Services |
La Jolla Pharma LLC
La Jolla Pharma LLC Pharmaceuticals: MajorHealth Technology Part of Innoviva, Inc., La Jolla Pharma LLC is a pharmaceutical company that manufactures pharmaceutical products. The private company is based in Dover, DE. | Health Technology |
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | Health Technology |
Tetraphase Pharmaceuticals Ireland Ltd.
 Tetraphase Pharmaceuticals Ireland Ltd. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals Ireland Ltd. is an Irish private company located in Dublin that manufactures basic pharmaceutical products. | Health Technology |
